Individual Endpoints Pose Challenge For US FDA In Review Of Rare Disease Drug
FDA reviewer describes difficulties in reviewing application for Mepsevii for Sly syndrome; the experience provides perspective for other companies seeking to use novel endpoints.
You may also be interested in...
The latest drug approval and development news from our US FDA Performance Tracker.
Novartis co-leads industry forum on preapproval access that aims to share best practices and engage patient groups; Janssen is launching three pilots to leverage collection of preapproval access data.